Abstract
Thirty-one aziridinylbenzoquinones were compared against five murine tumor models in vivo. Two intracerebral (ependymoblastoma and L-1210 leukemia) and three intraperitoneal (P-388 and L-1210 leukemia and B16 melanoma) systems were utilized. Excellent activity was observed for many compounds. Multiple long-term survivors were produced in the ependymoblastoma, P-388, and intraperitoneal L-1210 systems. Diethyl 2,5-bis(l-aziridinyl)-3,6-dioxo-l,4-cyclohexadiene-dicarbamate demonstrated superior activity in all five test systems. This compound also was reproducibly active against two colon tumors, a mammary tumor, and the intracerebrally implanted P-388 leukemia model.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
